Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94868
Title:
Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
Authors:
Young, R I; Ranson, Malcolm R; Chang, James; Lord, Brian I; Testa, Nydia G; Scarffe, J Howard
Abstract:
We examined the tolerability and safety of interleukin-6 (rhIL-6) when administered prior to and concurrent with vincristine, doxorubicin and dexamethasone (VAD) in patients with progressive multiple myeloma previously treated with VAD alone. Typical rhIL-6-related effects such as fever, chills, acute phase reactions and reversible abnormalities in liver function tests were observed. The study examined whether rhIL-6 predictably modulated indices of myeloma activity. No consistent, predictable change in myeloma-related parameters was documented upon rhIL-6 administration for either 8 days or 11 days prior to and concurrent with VAD. Two patients showed improved sensitivity to VAD chemotherapy when this was administered with rhIL-6. The overall response rate to rhIL-6 and VAD therapy in this study of relapsed and refractory patients was 50%, comparable to our previous experience with VAD alone in this cohort of patients.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, U.K.
Citation:
Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. 1997, 33 (2):307-11 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Feb-1997
URI:
http://hdl.handle.net/10541/94868
DOI:
10.1016/S0959-8049(96)00383-8
PubMed ID:
9135507
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorYoung, R Ien
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorChang, Jamesen
dc.contributor.authorLord, Brian Ien
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorScarffe, J Howarden
dc.date.accessioned2010-03-24T14:19:04Z-
dc.date.available2010-03-24T14:19:04Z-
dc.date.issued1997-02-
dc.identifier.citationPhase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. 1997, 33 (2):307-11 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid9135507-
dc.identifier.doi10.1016/S0959-8049(96)00383-8-
dc.identifier.urihttp://hdl.handle.net/10541/94868-
dc.description.abstractWe examined the tolerability and safety of interleukin-6 (rhIL-6) when administered prior to and concurrent with vincristine, doxorubicin and dexamethasone (VAD) in patients with progressive multiple myeloma previously treated with VAD alone. Typical rhIL-6-related effects such as fever, chills, acute phase reactions and reversible abnormalities in liver function tests were observed. The study examined whether rhIL-6 predictably modulated indices of myeloma activity. No consistent, predictable change in myeloma-related parameters was documented upon rhIL-6 administration for either 8 days or 11 days prior to and concurrent with VAD. Two patients showed improved sensitivity to VAD chemotherapy when this was administered with rhIL-6. The overall response rate to rhIL-6 and VAD therapy in this study of relapsed and refractory patients was 50%, comparable to our previous experience with VAD alone in this cohort of patients.en
dc.language.isoenen
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow-
dc.subject.meshDexamethasone-
dc.subject.meshDoxorubicin-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInterleukin-6-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMultiple Myeloma-
dc.subject.meshRecombinant Proteins-
dc.subject.meshVincristine-
dc.titlePhase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.